Ranch Capital Advisors Inc. Boosts Holdings in Johnson & Johnson (NYSE:JNJ)

Ranch Capital Advisors Inc. increased its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.8% in the fourth quarter, HoldingsChannel.com reports. The firm owned 10,547 shares of the company’s stock after buying an additional 85 shares during the period. Johnson & Johnson accounts for approximately 1.5% of Ranch Capital Advisors Inc.’s portfolio, making the stock its 17th largest holding. Ranch Capital Advisors Inc.’s holdings in Johnson & Johnson were worth $1,863,000 as of its most recent filing with the SEC.

Other hedge funds have also recently made changes to their positions in the company. Glassy Mountain Advisors Inc. acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at $35,000. Retirement Financial Solutions LLC purchased a new position in Johnson & Johnson during the 4th quarter worth $40,000. TD Capital Management LLC purchased a new stake in shares of Johnson & Johnson in the third quarter valued at about $48,000. VitalStone Financial LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $52,000. Finally, Iron Horse Wealth Management LLC boosted its holdings in shares of Johnson & Johnson by 112.8% in the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after acquiring an additional 159 shares in the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of research analyst reports. Credit Suisse Group boosted their price objective on shares of Johnson & Johnson from $168.00 to $170.00 in a report on Friday, May 5th. UBS Group initiated coverage on shares of Johnson & Johnson in a research report on Tuesday, March 28th. They set a “neutral” rating and a $164.00 target price for the company. StockNews.com initiated coverage on shares of Johnson & Johnson in a research report on Thursday, May 18th. They set a “strong-buy” rating for the company. Morgan Stanley lifted their target price on shares of Johnson & Johnson from $179.00 to $183.00 and gave the stock an “equal weight” rating in a research report on Wednesday, April 19th. Finally, Atlantic Securities cut their target price on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a research report on Wednesday, April 19th. Seven investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $173.00.

Insiders Place Their Bets

In other Johnson & Johnson news, insider James D. Swanson sold 1,062 shares of the firm’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the completion of the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at approximately $1,425,191.90. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.20% of the stock is owned by company insiders.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $154.41 on Friday. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $183.35. The firm has a 50 day moving average price of $159.89 and a 200 day moving average price of $165.86. The company has a market cap of $401.27 billion, a price-to-earnings ratio of 32.30, a PEG ratio of 2.67 and a beta of 0.53. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.85 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, April 18th. The company reported $2.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.51 by $0.17. Johnson & Johnson had a net margin of 13.22% and a return on equity of 36.13%. The firm had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. During the same period in the previous year, the firm earned $2.67 earnings per share. Johnson & Johnson’s revenue was up 5.6% compared to the same quarter last year. Sell-side analysts predict that Johnson & Johnson will post 10.66 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 6th. Shareholders of record on Tuesday, May 23rd will be issued a dividend of $1.19 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.13. This represents a $4.76 annualized dividend and a yield of 3.08%. The ex-dividend date is Monday, May 22nd. Johnson & Johnson’s dividend payout ratio (DPR) is currently 99.58%.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.